ALSO NOTED: Alpharma to proceed with painkiller trial; Emerillon to buy HemaX shares; SciGen inks distribution deal; and much m

> Alpharma got a green light from the FDA to launch a Phase II trial of an abuse-resistant painkiller. Report [1]

> Emerillon Therapeutics has signed a deal to buy all outstanding shares of HemaX Genome. Article [2]

> Singapore-based SciGen has inked a $145 million-plus deal to supply China with its Hepatitis B vaccine. Report [3]

> Crucell will pocket $1 million and stands to gain much more with Merck's decision to use its production technology to develop a hepatitis C vaccine. Article [4]

> Bangladesh's Beximco Pharmaceuticals became the first drug company in that country to go public on the UK market, raising $21 million. Release [5]

> Micro Therapeutics says that ev3 has offered to buy the 30 percent of shares it doesn't already own. Report [6]

> Agensys has signed a collaboration deal with Sanofi Pasteur to develop new vaccine products directed at colorectal and prostate cancers. Release [7]

And Finally... Researchers are focused on using adult stem cell injections to repair damaged cardiac tissue. Article [8]